细胞外囊泡在炎症性肠病中的治疗应用
Sang Hyun Kim1, Bora Keum1, Sooun Kwak2
1Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.
International journal of molecular sciences
|January 23, 2024
概括
细胞外囊泡 (EVs) 在生物药物失败时显示出治疗炎症性肠病 (IBD) 的前景. 研究探讨了它们的治疗潜力,并将其用作IBD患者的药物输送系统.
科学领域:
- 胃肠道学和免疫学
- 生物技术和纳米医学
背景情况:
- 生物疗法已经推进了炎症性肠病 (IBD) 治疗.
- 很大一部分IBD患者对生物药物表现出不反应或失去反应.
- 新的治疗策略对于有效管理IBD至关重要.
研究的目的:
- 审查细胞外囊泡 (EV) 在IBD中的生物发生,内容和作用.
- 探索电动汽车隔离和分析技术的进展.
- 评估EV在IBD中的治疗潜力及其作为药物输送系统的应用.
主要方法:
- 文献综述侧重于细胞外囊泡 (EVs) 和炎症性肠病 (IBD).
- 对IBD病变发生过程中EV的产生,内容和功能的当前研究进行分析.
- 研究EVs对IBD的新兴隔离,分析和治疗应用.
主要成果:
- 细胞外囊泡 (EVs) 参与IBD的发病,影响肠道屏障的完整性和代谢物驱逐.
- 电动汽车具有作为IBD治疗剂和药物载体的潜力.
- 隔离和分析方面的进步正在加强对电动汽车的研究和应用.
结论:
- 细胞外囊泡 (EVs) 代表了IBD创新疗法的前沿.
- 对基于EV的药物输送系统的进一步研究可以克服IBD当前的治疗限制.
- 电动车为管理炎症性肠病提供了多方面的方法.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
139
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K


